Utilizing targeted gene therapy with nanoparticles binding alpha v Beta 3 for imaging and treating choroidal Neovascularization

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Salehi Had, Hani ^a   Roh, Mi In ^a   Giani, Andrea ^a   Hisatomi, Toshio ^a   Nakao, Shintaro ^a   Kim, Ivana K ^a   Gragoudas, Evangelos S ^a   Vavvas, Demetrios ^a   Guccione, Samira ^b   Miller, Joan W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; NANOPARTICLE; RAF PROTEIN; RHODAMINE; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; GENE TARGETING; GENE THERAPY; IMAGING; IN VIVO STUDY; MALE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OPTICAL COHERENCE TOMOGRAPHY; PLASMID; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SUBRETINAL NEOVASCULARIZATION; ANIMAL; DOMINANT GENE; ENDOTHELIUM CELL; GENETICS; LASER; LASER COAGULATION; MACROPHAGE; METABOLISM; METHODOLOGY; MUTATION;

RATTUS;

ANIMALS; APOPTOSIS; CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL CELLS; GENE THERAPY; GENES, DOMINANT; GREEN FLUORESCENT PROTEINS; INTEGRIN ALPHAVBETA3; LASERS; LIGHT COAGULATION; MACROPHAGES; MALE; MUTATION; PLASMIDS; RATS; RHODAMINES;

EID: 79955730718     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018864     Document Type: Article

References (45)

1. Pascolini D, Mariotti SP, Pokharel GP, Pararajasegaram R, Etya'ale D, et al. (2004) 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol 11 (2): 67-115.
2. Congdon N, O'Colmain B, Klaver CC, Klein R, Muñoz B, et al. (2004) Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122 (4): 477-85.
3. Jager RD, Mieler WF, Miller JW, (2008) Age-related macular degeneration. N Engl J Med 358 (24): 2606-17.
4. Ferris FL 3rd, Fine SL, Hyman L, (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102 (11): 1640-2.
5. Seddon JM, Chen CA, (2004) The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 44 (4): 17-39.
6. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, et al. (2003) Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136 (3): 407-18.
7. D'Amato RJ, Adamis AP, (1995) Angiogenesis inhibition in age-related macular degeneration. Ophthalmology 102 (9): 1261-2.
8. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR Jr, et al. (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (27): 2805-16.
9. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (14): 1419-31.
10. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V, (2005) Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46 (2): 726-33.
11. Bressler NM, (2009) Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 116 (10 Suppl): S15-23.
12. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, et al. (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296 (5577): 2404-7.
13. Guccione S, Li KC, Bednarski MD, (2004) Molecular imaging and therapy directed at the neovasculature in pathologies. How imaging can be incorporated into vascular-targeted delivery systems to generate active therapeutic agents. IEEE Eng Med Biol Mag 23 (5): 50-6.
14. Kobayashi H, Lin PC, (2006) Nanotechnology for antiangiogenic cancer therapy. Nanomedicine (Lond) 1 (1): 17-22.
15. Thomson H, Lotery A, (2009) The promise of nanomedicine for ocular disease. Nanomedicine (Lond) 4 (6): 599-604.
16. Yancopoulos GD, Klagsbrun M, Folkman J, (1998) Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 93 (5): 661-4.
17. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, et al. (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (7): 1157-64.
18. Tucker GC, (2003) Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 4 (6): 722-31.
19. Kumar CC, Armstrong L, Yin Z, Malkowski M, Maxwell E, et al. (2000) Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. Adv Exp Med Biol 476: 169-80.
20. Stromblad S, Cheresh DA, (1996) Integrins, angiogenesis and vascular cell survival. Chem Biol 3 (11): 881-5.
21. Scatena M, Giachelli C, (2002) The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. Trends Cardiovasc Med 12 (2): 83-8.
22. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA, (1996) Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab Invest 75 (4): 563-73.
23. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, et al. (1996) Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci U S A 93 (18): 9764-9.
24. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT, (1996) Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 2 (5): 529-33.
25. Kamizuru H, Kimura H, Yasukawa T, Tabata Y, Honda Y, et al. (2001) Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci 42 (11): 2664-72.
26. Honda S, Nagai T, Negi A, (2009) Anti-angiogenic effects of non-peptide integrin alphavbeta3 specific antagonist on laser-induced choroidal neovascularization in mice. Graefes Arch Clin Exp Ophthalmol 247 (4): 515-22.
27. Berinstein A, Roivainen M, Hovi T, Mason PW, Baxt B, (1995) Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol 69 (4): 2664-6.
28. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR, (1993) Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73 (2): 309-19.
29. Heidecker G, Huleihel M, Cleveland JL, Kolch W, Beck TW, et al. (1990) Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol 10 (6): 2503-12.
30. Zacks DN, Ezra E, Terada Y, Michaud N, Connolly E, et al. (2002) Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest Ophthalmol Vis Sci 43 (7): 2384-91.
31. She H, Nakazawa T, Matsubara A, Hisatomi T, Young TA, et al. (2007) Reduced photoreceptor damage after photodynamic therapy through blockade of nitric oxide synthase in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci 48 (5): 2268-77.
32. Renno RZ, Terada Y, Haddadin MJ, Michaud NA, Gragoudas ES, et al. (2004) Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol 122 (7): 1002-11.
33. Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, et al. (2003) Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci 44 (6): 2743-9.
34. Marneros AG, She H, Zambarakji H, Hashizume H, Connolly EJ, et al. (2007) Endogenous endostatin inhibits choroidal neovascularization. FASEB J 21 (14): 3809-18.
35. Zambarakji HJ, Nakazawa T, Connolly E, Lane AM, Mallemadugula S, et al. (2006) Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization. Invest Ophthalmol Vis Sci 47 (6): 2623-31.
36. Nakazawa T, Matsubara A, Noda K, Hisatomi T, She H, et al. (2006) Characterization of cytokine responses to retinal detachment in rats. Mol Vis 12: 867-78.
37. Gaudana R, Ananthula HK, Parenky A, Mitra AK, (2010 Sep) Ocular Drug Delivery. AAPS J 12 (3): 348-60.
38. Robbins SG, Brem RB, Wilson DJ, O'Rourke LM, Robertson JE, et al. (1994) Immunolocalization of integrins in proliferative retinal membranes. Invest Ophthalmol Vis Sci 35 (9): 3475-85.
39. Brooks PC, Strömblad S, Klemke R, Visscher D, Sarkar FH, et al. (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96 (4): 1815-22.
40. Brooks PC, Clark RA, Cheresh DA, (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (5158): 569-71.
41. Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, et al. (2009) CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460 (7252): 225-30.
42. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, et al. (2009) Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther 16 (5): 645-59.
43. Hüser M, Luckett J, Chiloeches A, Mercer K, Iwobi M, et al. (2001) MEK kinase activity is not necessary for Raf-1 function. EMBO J 20 (8): 1940-51.
44. Tang R, Long J, Chen B, (2009) Expression of integrin alphavbeta3, tissue factor, and vascular endothelial growth factor in experimental choroidal neovascularization. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34 (8): 762-7.
45. Ning A, Cui J, Maberley D, Ma P, Matsubara J, (2008) Expression of integrins in human proliferative diabetic retinopathy membranes. Can J Ophthalmol 43 (6): 683-8.